Catalyst Dossier · compiled by CeliA 🧫
MEDICURE INC (MCUJF)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 3
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Medicure Inc. (MCUJF) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.80. Its lead asset, MC-1 (Pyridoxal 5'-phosphate), is in Phase 3 development for Coronary Artery Bypass Graft Surgery (CABG) complications, with a separate Phase 3 program in Pyridox(am)ine 5'-Phosphate Oxidase Deficiency (PNPO Deficiency). A key Phase 3 readout for the PNPO Deficiency indication is estimated around November 15, 2026.
The catalyst path
- 2026-11-15 (est.)Phase 3 · Pyridoxal Phosphateimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Short Tirofiban | Phase 2 | Myocardial Infarction |
| (MC-1) Pyridoxal-5'-phosphate | Phase 2 | Coronary Artery Bypass Graft Surgery |
| (MC-1) Pyridoxal 5'-phosphate | Phase 3 | Coronary Artery Bypass Graft Surgery |
| pyridoxal-5'-phosphate with and without ACE inhibitor | Phase 2 | Diabetes Mellitus Type 2 |
| Pyridoxal Phosphate | Phase 3 | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency |
Price & technical context
3-month
+176.1%
6-month
+131.3%
12-month
+160.6%
52-wk range
$0.67–$1.93
vs 50-day MA
+60.1%
vs 200-day MA
+105.5%
Realized vol
78.7%
Max drawdown
-45.0%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MCUJF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.